Japan · Delayed Price · Currency is JPY Renascience Company Description
Renascience Inc. engages in the development and commercialization of pharmaceuticals and medical devices in Japan.
The company is developing RS5614, a PAI-1 inhibitor product candidate for use in the treatment of chronic myeloid leukemia, malignant melanoma, non-small cell lung cancer, novel coronavirus infections, and FGF23-related hypophosphatemic rickets that is in Phase 3 clinical trials; RS5441, a PAI-1 inhibitor for use in dermatological diseases that is in Phase I clinical trials; and RS8001, a water-soluble vitamin for use in the treatment of premenstrual syndrome/premenstrual dysphoric mood disorder, autism spectrum disorder, and menopausal disorder, which is in Phase 2 clinical trials.
It is also developing RS9001, a disposable ultrafine endoscope; artificial intelligence based medical solutions; and diagnostic solutions.
The company was incorporated in 2000 and is headquartered in Tokyo, Japan.
| Country | Japan |
| Founded | 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Toshio Miyata |
Contact Details
Address: 401 Kyodo Building Tokyo, 103-0023 Japan | |
| Phone | 81 3 6262 0873 |
| Website | renascience.co.jp |
Stock Details
| Ticker Symbol | 4889 |
| Exchange | Tokyo Stock Exchange |
| Fiscal Year | April - March |
| Reporting Currency | JPY |
| ISIN Number | JP3981100005 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Keisuke Furuta | Chief Executive Officer |